{"id":"maintaining-carbapenem-therapy","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Vomiting"},{"rate":"2-5","effect":"Headache"},{"rate":"3-7","effect":"Phlebitis at injection site"},{"rate":"0.5-1","effect":"Seizures (rare, especially with renal impairment)"},{"rate":"1-3","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1240705","moleculeType":"Small molecule","molecularWeight":"153.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carbapenems are broad-spectrum beta-lactam antibiotics that penetrate bacterial cell walls and irreversibly bind to penicillin-binding proteins, preventing the cross-linking of peptidoglycan strands essential for cell wall integrity. This leads to cell wall rupture and bacterial death. They are effective against a wide range of gram-positive, gram-negative, and anaerobic bacteria, including many beta-lactamase-producing organisms.","oneSentence":"Carbapenem antibiotics inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:49.450Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections (gram-positive, gram-negative, and anaerobic)"},{"name":"Hospital-acquired infections"},{"name":"Intra-abdominal infections"},{"name":"Respiratory tract infections"},{"name":"Urinary tract infections"}]},"trialDetails":[{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT07039955","phase":"NA","title":"Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2025-07-14","conditions":"Carbapenemase-Producing Enterobacteriaceae (CPE), Healthcare-Associated Infections (HAIs)","enrollment":5760},{"nctId":"NCT02265445","phase":"PHASE4","title":"Deescalating Carbapenems in Hospital Setting","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-06","conditions":"Urinary Infection, Digestive Infection, Biliary Infection","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Maintaining carbapenem therapy","genericName":"Maintaining carbapenem therapy","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbapenem antibiotics inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking. Used for Serious bacterial infections (gram-positive, gram-negative, and anaerobic organisms), Hospital-acquired infections, Sepsis and severe infections in hospitalized patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}